N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS
申请人:Incyte Corporation
公开号:EP2432555B1
公开(公告)日:2014-04-30
US8716303B2
申请人:——
公开号:US8716303B2
公开(公告)日:2014-05-06
US9334274B2
申请人:——
公开号:US9334274B2
公开(公告)日:2016-05-10
[EN] N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-(HÉTÉRO)ARYL-PYRROLIDINE DE PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES ET PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES EN TANT QU'INHIBITEURS DE LA JANUS KINASE
申请人:INCYTE CORP
公开号:WO2010135650A1
公开(公告)日:2010-11-25
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula (I): which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
申请人:Rodgers James D.
公开号:US20100298334A1
公开(公告)日:2010-11-25
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I:
which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.